Clinical Trials

46 enrolled

Small Cell Lung Carcinoma

NCT06623422 2026-04-14

INTerpath-009

Phase 3 Recruiting

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07155174 2026-04-14

SEZanne

180 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07502300 2026-04-14

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

562 enrolled

Small Cell Lung Carcinoma

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

94 enrolled

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT01386385 2026-04-13

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

53 enrolled 21 charts

Phase NA Active not recruiting

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT02194738 2026-04-13

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02609776 2026-04-13

CHRYSALIS

751 enrolled 2 FDA

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Phase 2 Active not recruiting

Lung Neoplasms

NCT03965689 2026-04-13

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

27 enrolled 13 charts

Lung Neoplasms

NCT04077463 2026-04-13

Chrysalis-2

701 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

12 enrolled 25 charts

Phase 3 Active not recruiting

Lung Neoplasms

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05198830 2026-04-13

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

42 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT05498428 2026-04-13

PALOMA-2

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

21 enrolled

SCLC,Extensive Stage

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06793215 2026-04-13

Krascendo 2

Phase 3 Recruiting

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07190248 2026-04-13

KANDLELIT-007

Phase 3 Recruiting

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221474 2026-04-13

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07227597 2026-04-13

MK-6070-003

Phase 1/2 Recruiting

170 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Cancer Extensive Stage

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT06624059 2026-04-08

HORIZON 2

11 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07241767 2026-04-08

A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

200 enrolled

Phase 2 Active not recruiting

Lung Neoplasms

NCT03485209 2026-04-07

innovaTV 207

352 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03737994 2026-04-07

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts